Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals, Inc. - Common Stock (NQ: SYRS )

0.2100 UNCHANGED
Streaming Delayed Price Updated: 11:22 AM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Earnings Outlook For Syros Pharmaceuticals
Via Benzinga
Syros Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Syros Pharmaceuticals
Via Business Wire
Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders
Syros Pharmaceuticals Inc received notice from Pfizer Inc (NYSE: PFE), as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated... 
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Sidoti Events, LLC's Virtual June Small-Cap Conference
Via ACCESSWIRE
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Present at JMP Securities 2023 Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 93 stocks made new 52-week lows. 
Via Benzinga
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday
Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in... 
Via Benzinga
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
From Syros Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.